[
{
  "title": "Accelerated phase chronic myeloid leukemia: Diagnosis and treatment",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "PRETREATMENT EVALUATION",
      "subheadings": [
        "Clinical and laboratory",
        "History",
        "Physical examination",
        "Performance status",
        "Laboratory",
        "Clinical tests",
        "BCR-ABL1",
        "Bone marrow morphology",
        "Karyotype",
        "Mutation testing — BCR-ABL1",
        "Hematopoietic cell transplantation evaluation"
      ]
    },
    {
      "heading": "DIAGNOSIS OF AP CML",
      "subheadings": [
        "World Health Organization",
        "Other models",
        "European LeukemiaNet (ELN)",
        "MDACC (MD Anderson Cancer Center)",
        "Sokal"
      ]
    },
    {
      "heading": "MANAGEMENT",
      "subheadings": [
        "De novo versus transformed AP",
        "Treatment of de novo AP CML",
        "Selection of a TKI",
        "Outcomes"
      ]
    }
  ]
},

{
  "title": "Treatment of chronic myeloid leukemia in blast crisis",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "DEFINITION OF BLAST CRISIS",
      "subheadings": [
        "World Health Organization criteria",
        "Myeloid blast crisis",
        "Lymphoid blast crisis",
        "Extramedullary blast proliferation"
      ]
    },
    {
      "heading": "EVALUATION UPON TRANSFORMATION",
      "subheadings": [
        "Laboratory studies",
        "Bone marrow examination",
        "BCR-ABL1 mutation analysis",
        "HLA typing and transplant referral"
      ]
    },
    {
      "heading": "REMISSION INDUCTION",
      "subheadings": [
        "Goals of therapy",
        "Myeloid blast crisis",
        "Lymphoid blast crisis",
        "Choice of TKI"
      ]
    },
    {
      "heading": "POST-REMISSION THERAPY",
      "subheadings": [
        "Assessment of HCT eligibility",
        "Eligible for HCT",
        "Ineligible for HCT"
      ]
    },
    {
      "heading": "TREATMENT AFTER FAILURE OF INITIAL THERAPY",
      "subheadings": [
        "Alternative TKIs",
        "Chemotherapy combinations",
        "Clinical trials"
      ]
    }
  ]
},

{
  "title": "Clinical manifestations and diagnosis of chronic myeloid leukemia",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "EPIDEMIOLOGY",
      "subheadings": [
        "Incidence and prevalence",
        "Risk factors"
      ]
    },
    {
      "heading": "CLINICAL MANIFESTATIONS",
      "subheadings": [
        "Chronic phase",
        "Accelerated phase",
        "Blast crisis",
        "Systemic symptoms"
      ]
    },
    {
      "heading": "PATHOLOGIC FEATURES",
      "subheadings": [
        "Peripheral blood",
        "Bone marrow biopsy"
      ]
    },
    {
      "heading": "GENETICS",
      "subheadings": [
        "Philadelphia chromosome",
        "BCR-ABL1 fusion gene",
        "Molecular variants"
      ]
    },
    {
      "heading": "DIAGNOSIS",
      "subheadings": [
        "Cytogenetic testing",
        "FISH",
        "RT-PCR"
      ]
    },
    {
      "heading": "DIFFERENTIAL DIAGNOSIS",
      "subheadings": [
        "Leukemoid reaction",
        "Other myeloproliferative neoplasms",
        "Philadelphia chromosome-positive leukemias"
      ]
    },
    {
      "heading": "PROGNOSIS",
      "subheadings": [
        "Risk stratification",
        "Sokal score",
        "Hasford (Euro) score",
        "EUTOS score"
      ]
    }
  ]
}
,
{
  "title": "Clinical manifestations and diagnosis of chronic myeloid leukemia",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "EPIDEMIOLOGY",
      "subheadings": [
        "Incidence and prevalence",
        "Risk factors"
      ]
    },
    {
      "heading": "CLINICAL MANIFESTATIONS",
      "subheadings": [
        "Chronic phase",
        "Accelerated phase",
        "Blast crisis",
        "Systemic symptoms"
      ]
    },
    {
      "heading": "PATHOLOGIC FEATURES",
      "subheadings": [
        "Peripheral blood",
        "Bone marrow biopsy"
      ]
    },
    {
      "heading": "GENETICS",
      "subheadings": [
        "Philadelphia chromosome",
        "BCR-ABL1 fusion gene",
        "Molecular variants"
      ]
    },
    {
      "heading": "DIAGNOSIS",
      "subheadings": [
        "Cytogenetic testing",
        "FISH",
        "RT-PCR"
      ]
    },
    {
      "heading": "DIFFERENTIAL DIAGNOSIS",
      "subheadings": [
        "Leukemoid reaction",
        "Other myeloproliferative neoplasms",
        "Philadelphia chromosome-positive leukemias"
      ]
    },
    {
      "heading": "PROGNOSIS",
      "subheadings": [
        "Risk stratification",
        "Sokal score",
        "Hasford (Euro) score",
        "EUTOS score"
      ]
    }
  ]
}
,
{
  "title": "Initial treatment of chronic myeloid leukemia in chronic phase",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "GOALS OF CARE",
      "subheadings": [
        "Achieve clinical remission",
        "Maintain long-term disease control",
        "Prevent progression to accelerated phase or blast crisis",
        "Optimize quality of life",
        "Consider treatment-free remission"
      ]
    },
    {
      "heading": "PRETREATMENT EVALUATION",
      "subheadings": [
        "Clinical history and physical examination",
        "Performance status and comorbidities",
        "Laboratory studies",
        "Complete blood count with differential",
        "Serum chemistries",
        "Hepatitis screening",
        "Electrocardiogram",
        "BCR-ABL1 quantitative PCR",
        "Bone marrow examination",
        "Cytogenetic analysis",
        "Risk stratification scores"
      ]
    },
    {
      "heading": "RATIONALE FOR TKI TREATMENT",
      "subheadings": [
        "Role of BCR-ABL1 tyrosine kinase",
        "Efficacy of tyrosine kinase inhibitors",
        "Comparison with non-TKI therapies"
      ]
    },
    {
      "heading": "CHOOSING A TYROSINE KINASE INHIBITOR",
      "subheadings": [
        "Risk score assessment",
        "Treatment-free remission as a goal",
        "Patient comorbidities",
        "Adverse effect profiles",
        "Drug availability and cost",
        "Patient preference"
      ]
    },
    {
      "heading": "INDIVIDUAL TYROSINE KINASE INHIBITORS",
      "subheadings": [
        "Imatinib",
        "Nilotinib",
        "Dasatinib",
        "Bosutinib",
        "Other TKIs"
      ]
    },
    {
      "heading": "TREATMENT RESPONSE",
      "subheadings": [
        "Hematologic response",
        "Cytogenetic response",
        "Molecular response",
        "Response milestones",
        "Failure to achieve milestones"
      ]
    },
    {
      "heading": "MONITORING TOXICITY",
      "subheadings": [
        "History and physical examination",
        "Laboratory monitoring",
        "Electrocardiographic monitoring",
        "Management of common adverse effects",
        "Hematologic toxicities",
        "Cardiovascular toxicities",
        "Pulmonary toxicities",
        "Hepatic and pancreatic toxicities"
      ]
    },
    {
      "heading": "MANAGING TOXICITY",
      "subheadings": [
        "Dose reduction",
        "Temporary treatment interruption",
        "Switching to an alternative TKI",
        "Supportive care measures"
      ]
    },
    {
      "heading": "TREATMENT-FREE REMISSION",
      "subheadings": [
        "Eligibility criteria",
        "Monitoring during treatment discontinuation",
        "Management of molecular relapse"
      ]
    }
  ]
}
,
{
  "title": "Cellular and molecular biology of chronic myeloid leukemia",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "CELL OF ORIGIN",
      "subheadings": [
        "Hematopoietic stem cell origin",
        "Leukemia stem cells",
        "Clonality and stem cell properties"
      ]
    },
    {
      "heading": "THE BCR-ABL1 FUSION PROTEIN",
      "subheadings": [
        "BCR gene",
        "ABL1 gene",
        "Structure and function of BCR-ABL1",
        "Variants of BCR-ABL1"
      ]
    },
    {
      "heading": "BCR-ABL1 SIGNALING PATHWAYS",
      "subheadings": [
        "Tyrosine kinase activity",
        "Kinase-dependent signaling",
        "Kinase-independent pathways",
        "Downstream signaling cascades"
      ]
    },
    {
      "heading": "PATHOGENESIS OF CHRONIC PHASE CML",
      "subheadings": [
        "Uncontrolled proliferation",
        "Disordered maturation",
        "Escape from apoptosis",
        "Altered interaction with bone marrow microenvironment"
      ]
    },
    {
      "heading": "PROGRESSION TO ADVANCED PHASES",
      "subheadings": [
        "Accelerated phase",
        "Blast crisis",
        "Genetic instability",
        "Differentiation arrest"
      ]
    },
    {
      "heading": "MOUSE AND XENOGRAFT MODELS OF CML",
      "subheadings": [
        "Retroviral transduction models",
        "Transgenic mouse models",
        "Xenograft models"
      ]
    }
  ]
}
,
{
  "title": "Molecular genetics of chronic myeloid leukemia",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "THE PHILADELPHIA CHROMOSOME",
      "subheadings": [
        "Discovery of the Philadelphia chromosome",
        "t(9;22) translocation",
        "Cytogenetic features"
      ]
    },
    {
      "heading": "BCR-ABL1 GENE AND TRANSCRIPTS",
      "subheadings": [
        "BCR and ABL1 gene structure",
        "Breakpoint regions",
        "p210, p190 and p230 transcripts"
      ]
    },
    {
      "heading": "DETECTION OF BCR-ABL1",
      "subheadings": [
        "Conventional cytogenetics",
        "FISH",
        "RT-PCR",
        "Quantitative PCR"
      ]
    },
    {
      "heading": "MOLECULAR RESPONSE AND MONITORING",
      "subheadings": [
        "International Scale",
        "Major molecular response",
        "Deep molecular response",
        "Minimal residual disease"
      ]
    },
    {
      "heading": "GENETIC VARIANTS AND ATYPICAL CML",
      "subheadings": [
        "Variant translocations",
        "Ph-negative CML",
        "Atypical CML"
      ]
    },
    {
      "heading": "GENETIC INSTABILITY AND PROGRESSION",
      "subheadings": [
        "Additional chromosomal abnormalities",
        "Tumor suppressor gene alterations",
        "Mechanisms of disease progression"
      ]
    }
  ]
}
,
{
  "title": "Overview of the treatment of chronic myeloid leukemia",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": []
    },
    {
      "heading": "DISEASE PHASES",
      "subheadings": [
        "Chronic phase",
        "Accelerated phase",
        "Blast phase"
      ]
    },
    {
      "heading": "PRETREATMENT EVALUATION",
      "subheadings": [
        "Clinical assessment",
        "Laboratory evaluation",
        "Cytogenetic and molecular testing",
        "Risk stratification scores"
      ]
    },
    {
      "heading": "TREATMENT OVERVIEW",
      "subheadings": [
        "Goals of therapy",
        "Role of tyrosine kinase inhibitors",
        "Treatment selection principles"
      ]
    },
    {
      "heading": "INITIAL TREATMENT",
      "subheadings": [
        "Imatinib",
        "Second-generation TKIs",
        "Risk-adapted therapy"
      ]
    },
    {
      "heading": "MONITORING RESPONSE",
      "subheadings": [
        "Hematologic response",
        "Cytogenetic response",
        "Molecular response",
        "Response milestones"
      ]
    },
    {
      "heading": "TREATMENT RESISTANCE AND INTOLERANCE",
      "subheadings": [
        "Definition of resistance",
        "ABL1 kinase domain mutations",
        "Management strategies"
      ]
    },
    {
      "heading": "TKI DISCONTINUATION",
      "subheadings": [
        "Treatment-free remission",
        "Eligibility criteria",
        "Monitoring after discontinuation"
      ]
    },
    {
      "heading": "ROLE OF TRANSPLANTATION",
      "subheadings": [
        "Indications for allogeneic HCT",
        "Timing of transplantation"
      ]
    }
  ]
}
,
{
  "title": "Reverse Warburg Effect in a Patient With Aggressive B-Cell Lymphoma",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": [
        "Lactic acidosis in cancer",
        "Type A and Type B lactic acidosis",
        "Association with aggressive lymphomas"
      ]
    },
    {
      "heading": "CANCER METABOLISM BACKGROUND",
      "subheadings": [
        "Warburg effect",
        "Reverse Warburg effect",
        "Stromal–epithelial metabolic coupling"
      ]
    },
    {
      "heading": "CASE PRESENTATION",
      "subheadings": [
        "Clinical presentation",
        "Laboratory findings",
        "Imaging findings",
        "Diagnosis"
      ]
    },
    {
      "heading": "PATHOPHYSIOLOGY",
      "subheadings": [
        "Role of lactate",
        "Mitochondrial dysfunction",
        "Tumor–stromal interactions"
      ]
    },
    {
      "heading": "MANAGEMENT AND OUTCOME",
      "subheadings": [
        "Therapeutic approach",
        "Response to treatment",
        "Clinical outcome"
      ]
    },
    {
      "heading": "DISCUSSION",
      "subheadings": [
        "Clinical implications",
        "Prognostic significance",
        "Comparison with previous reports"
      ]
    },
    {
      "heading": "CONCLUSION",
      "subheadings": []
    }
  ]
}
,
{
  "title": "Acute Liver Failure Secondary to Malignant Infiltration",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": [
        "Definition of acute liver failure",
        "Common causes of acute liver failure",
        "Malignant infiltration as a rare cause"
      ]
    },
    {
      "heading": "METHODS",
      "subheadings": [
        "Study design",
        "Patient selection",
        "Data collection"
      ]
    },
    {
      "heading": "CLINICAL PRESENTATION",
      "subheadings": [
        "Symptoms",
        "Laboratory abnormalities",
        "Radiological findings"
      ]
    },
    {
      "heading": "ETIOLOGY OF MALIGNANCY",
      "subheadings": [
        "Hematological malignancies",
        "Solid tumors"
      ]
    },
    {
      "heading": "DIAGNOSTIC APPROACH",
      "subheadings": [
        "Role of imaging",
        "Liver biopsy",
        "Differential diagnosis"
      ]
    },
    {
      "heading": "TREATMENT AND MANAGEMENT",
      "subheadings": [
        "Supportive care",
        "Chemotherapy",
        "Liver transplantation"
      ]
    },
    {
      "heading": "OUTCOMES",
      "subheadings": [
        "Mortality",
        "Survival outcomes"
      ]
    },
    {
      "heading": "DISCUSSION",
      "subheadings": [
        "Clinical challenges",
        "Therapeutic implications"
      ]
    },
    {
      "heading": "CONCLUSION",
      "subheadings": []
    }
  ]
}
,
{
  "title": "Adjuvant and Neoadjuvant Cancer Therapies: A Historical Review",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": [
        "Concept of adjuvant therapy",
        "Concept of neoadjuvant therapy"
      ]
    },
    {
      "heading": "HISTORICAL PERSPECTIVE",
      "subheadings": [
        "Early experimental evidence",
        "Development of adjuvant chemotherapy",
        "Evolution of neoadjuvant therapy"
      ]
    },
    {
      "heading": "PRINCIPLES OF DRUG DEVELOPMENT",
      "subheadings": [
        "Metastatic setting as a testing ground",
        "Translation to early-stage disease"
      ]
    },
    {
      "heading": "CLINICAL OUTCOMES",
      "subheadings": [
        "Breast cancer",
        "Colorectal cancer",
        "Other solid tumors"
      ]
    },
    {
      "heading": "TUMOR KINETICS AND TREATMENT RESPONSE",
      "subheadings": [
        "Tumor growth models",
        "Cell kill versus growth delay"
      ]
    },
    {
      "heading": "LIMITATIONS OF CURRENT APPROACHES",
      "subheadings": [
        "Reasons for limited survival benefit",
        "Biological explanations"
      ]
    },
    {
      "heading": "FUTURE DIRECTIONS",
      "subheadings": [
        "Rational trial design",
        "Improving adjuvant and neoadjuvant success"
      ]
    },
    {
      "heading": "CONCLUSION",
      "subheadings": []
    }
  ]
}
,
{
  "title": "Adjuvant and Neoadjuvant Cancer Therapies: A Historical Review",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": [
        "Concept of adjuvant therapy",
        "Concept of neoadjuvant therapy"
      ]
    },
    {
      "heading": "HISTORICAL PERSPECTIVE",
      "subheadings": [
        "Early experimental evidence",
        "Development of adjuvant chemotherapy",
        "Evolution of neoadjuvant therapy"
      ]
    },
    {
      "heading": "PRINCIPLES OF DRUG DEVELOPMENT",
      "subheadings": [
        "Metastatic setting as a testing ground",
        "Translation to early-stage disease"
      ]
    },
    {
      "heading": "CLINICAL OUTCOMES",
      "subheadings": [
        "Breast cancer",
        "Colorectal cancer",
        "Other solid tumors"
      ]
    },
    {
      "heading": "TUMOR KINETICS AND TREATMENT RESPONSE",
      "subheadings": [
        "Tumor growth models",
        "Cell kill versus growth delay"
      ]
    },
    {
      "heading": "LIMITATIONS OF CURRENT APPROACHES",
      "subheadings": [
        "Reasons for limited survival benefit",
        "Biological explanations"
      ]
    },
    {
      "heading": "FUTURE DIRECTIONS",
      "subheadings": [
        "Rational trial design",
        "Improving adjuvant and neoadjuvant success"
      ]
    },
    {
      "heading": "CONCLUSION",
      "subheadings": []
    }
  ]
}
,
{
  "title": "New Insights into Adjuvant Therapy for Localized Colon Cancer",
  "headings": [
    {
      "heading": "INTRODUCTION",
      "subheadings": [
        "Epidemiology of colon cancer",
        "Role of surgery",
        "Rationale for adjuvant therapy"
      ]
    },
    {
      "heading": "CURRENT DECISION-MAKING IN LOCALIZED COLON CANCER",
      "subheadings": [
        "Stage II disease",
        "Stage III disease",
        "Clinicopathologic risk factors"
      ]
    },
    {
      "heading": "STANDARD ADJUVANT CHEMOTHERAPY",
      "subheadings": [
        "Fluoropyrimidine-based therapy",
        "Oxaliplatin-containing regimens",
        "MOSAIC, NSABP, XELOXA trials"
      ]
    },
    {
      "heading": "DURATION OF ADJUVANT THERAPY",
      "subheadings": [
        "IDEA collaboration",
        "Three versus six months therapy",
        "CAPOX versus FOLFOX"
      ]
    },
    {
      "heading": "CIRCULATING TUMOR DNA AND MINIMAL RESIDUAL DISEASE",
      "subheadings": [
        "Concept of ctDNA",
        "Prognostic value of ctDNA",
        "Detection methods"
      ]
    },
    {
      "heading": "CTDNA-GUIDED ADJUVANT STRATEGIES",
      "subheadings": [
        "Low-risk stage II disease",
        "High-risk stage II and stage III disease",
        "Ongoing clinical trials"
      ]
    },
    {
      "heading": "FUTURE PERSPECTIVES",
      "subheadings": [
        "Personalized adjuvant therapy",
        "Integration of biomarkers"
      ]
    },
    {
      "heading": "CONCLUSION",
      "subheadings": []
    }
  ]
}



]